SecBot SecBot
8-K ·Filed Aug 6, 2026

DNLI

Denali Therapeutics Inc.
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001714899-26-000096
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Focus on AVLAYAH launch trajectory: Q3 guidance of $10-12M implies rapid quarter-over-quarter growth, which could drive upside if sustained. However, the DNL151 failure and DNL593 delay remove near-term pipeline catalysts. Monitor the Q3 revenue print and any updates on the DNL126 BLA submission timeline for 2027.

DirectionMixed
Confidencehigh
Horizonweeks

tividenofusp alfa-eknm

● Neutral Named in this 8-K
Impact
Phase
Approved (accelerated approval)
Time to market
Already approved and commercially launched in the U.S. (March 2026). Global regulatory submissions are expected to follow the ongoing Phase 2/3 COMPASS confirmatory trial.
Next catalyst
None dated

What to watchThe next near-term catalyst is Denali's Q3 2026 earnings report on November 4, 2026, where management's Q3 Avlayah revenue (guided $10-12M, up from $3.6M in Q2) will be the key commercial proof point. The longer-term binary is the confirmatory Phase 2/3 COMPASS trial readout, which will determine whether the accelerated approval converts to full approval, though no specific readout date has been announced.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$24.83
T+0 close · Aug 6, 2026 · via day close
Latest settled
−24.53%
T+60 · $18.74
Vs SPY
−22.39%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 7 $24.83entry
  2. T+1 · 3mo ago +0.68%α +0.71% · $25.00
  3. T+5 · 3mo ago −1.73%α −2.13% · $24.40
  4. T+20 · 2mo ago −10.27%α −9.87% · $22.28
  5. T+60 · 15d ago −24.53%α −22.39% · $18.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Denali Therapeutics reported Q2 2026 results with AVLAYAH generating $3.6M in its first full commercial quarter, beating consensus revenue estimates of $2.2M. EPS of -$0.68 missed consensus of -$0.47 due to commercial build costs and lower interest income. Q3 AVLAYAH revenue guidance of $10-12M signals accelerating uptake, partially offsetting the negative pipeline news of the DNL151 (LRRK2) Phase 2b failure and the DNL593 (FTD-GRN) data delay to 2027.

Key Financial Metrics

EPS
−$0.68
est −$0.47 · -44.7%
Revenue
$3.6M
est $2.2M · +63.6%
Rating
miss
Guidance
$10.0M-$12.0M
raised

Key Facts

  • AVLAYAH net product revenue of $3.6M in Q2 2026, first full quarter of launch
  • Q3 2026 AVLAYAH revenue guidance of $10.0M to $12.0M
  • EPS of -$0.68 vs consensus -$0.47 (miss of 44.7%)
  • Net loss of $127.6M vs $124.1M in Q2 2025
  • Cash, equivalents and marketable securities ~$940M at June 30; pro forma >$1.1B after $195M PRV sale in July
  • DNL151 (LRRK2) Phase 2b LUMA study failed; development discontinued in idiopathic Parkinson's
  • DNL593 (FTD-GRN) Phase 1/2 data now expected in 2027 (previously end of 2026)
  • FDA granted Orphan Drug Designation to DNL593 for FTD-GRN in August 2026

Financial Impact

Revenue beat of $1.4M (63.6%) vs consensus; EPS miss of $0.21 (44.7%) vs consensus; cash strengthened by $195M PRV sale

revenueepscash

Risk Factors

  • AVLAYAH launch may not sustain momentum if payer coverage or patient starts slow
  • DNL151 failure removes a major pipeline asset; DNL593 delay pushes key data out
  • Competition from other Hunter syndrome therapies (e.g., Takeda's Elaprase) and emerging BBB-penetrating drugs

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001714899-26-000096
Document: dnli-20260806.htm0001714899-26-000096
Document: 0001714899-26-000096-index-headers.html0001714899-26-000096
Document: 0001714899-26-000096-index.html0001714899-26-000096
Document: 0001714899-26-000096.txt0001714899-26-000096
8-K Data (Synthetic)0001714899-26-000096

Track record

17 reports on DNLI

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +23.19% at T+60 after the May 7, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
  2. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
  4. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
  5. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
  6. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
  7. Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
  8. Aug 6, 202614w ago 8-K Mixed 6/10 Viewing Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
  9. Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
  10. Jun 18, 202621w ago 8-K Bullish 6/10 Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (10h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026